Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s11523-011-0200-y http://scihub22266oqcxt.onion/10.1007/s11523-011-0200-y 22113391!ä!22113391 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Target+Oncol 2011 ; 6 (4): 227-33 Nephropedia Template TP {{tp|p=22113391|t=2011. Hypomagnesaemia and targeted anti-epidermal growth factor receptor (EGFR) agents |pdf=|usr=}}{{22113391}} gab.com Text Hypomagnesaemia and targeted anti-epidermal growth factor receptor (EGFR) agents JO: Target Oncol http://www.kidney.de/pget.php?&tw=1&pmid=22113391 #FOAvip Currently, targeted anti-epidermal growth factor receptor (EGFR) agents have an important role in the treatment of various cancers. These drugs, particularly anti-EGFR monoclonal antibodies, may induce electrolyte disorders, such as hypomagnesaemia and hypocalcaemia. Early symptoms of magnesium deficiency can easily go unrecognized. However, hypomagnesaemia can in rare cases lead to serious clinical manifestations, including cardiac arrhythmias or convulsions. The elective tubular expression of renal EGF/EGFR explains the mechanism of this class-related drug side effect. Inhibition of the EGFR induces a mutated-like transient receptor potential cation channel, subfamily M, member 6 (TRPM6) syndrome, characterized by urinary magnesium and calcium wasting. The risk of hypomagnesaemia is associated with treatment duration. It is a reversible toxicity; the recovery of magnesium serum levels is usually seen 4-6 weeks of stopping the anti-EGFR antibody. Using literature from peer-reviewed journals, this review reports the clinical trials findings and discusses the mechanisms and the treatment of hypomagnesaemia induced by anti-EGFR targeted agents. Twit Text FOAVip Hypomagnesaemia and targeted anti-epidermal growth factor receptor (EGFR) agents ????Target Oncol http://www.kidney.de/pget.php?&tw=1&pmid=22113391 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=22113391 #FOAvip English Wikipedia <ref>{{Cite pmid|22113391}}</ref> Hypomagnesaemia and targeted anti-epidermal growth factor receptor (EGFR) agents #MMPMID22113391 Costa A; Tejpar S; Prenen H; Van Cutsem E Target Oncol 2011[Dec]; 6 (4): 227-33 PMID22113391show ga Currently, targeted anti-epidermal growth factor receptor (EGFR) agents have an important role in the treatment of various cancers. These drugs, particularly anti-EGFR monoclonal antibodies, may induce electrolyte disorders, such as hypomagnesaemia and hypocalcaemia. Early symptoms of magnesium deficiency can easily go unrecognized. However, hypomagnesaemia can in rare cases lead to serious clinical manifestations, including cardiac arrhythmias or convulsions. The elective tubular expression of renal EGF/EGFR explains the mechanism of this class-related drug side effect. Inhibition of the EGFR induces a mutated-like transient receptor potential cation channel, subfamily M, member 6 (TRPM6) syndrome, characterized by urinary magnesium and calcium wasting. The risk of hypomagnesaemia is associated with treatment duration. It is a reversible toxicity; the recovery of magnesium serum levels is usually seen 4-6 weeks of stopping the anti-EGFR antibody. Using literature from peer-reviewed journals, this review reports the clinical trials findings and discusses the mechanisms and the treatment of hypomagnesaemia induced by anti-EGFR targeted agents. |Animals[MESH] |Antibodies, Monoclonal/*adverse effects/pharmacology[MESH] |ErbB Receptors/*antagonists & inhibitors/metabolism[MESH] |Humans[MESH] |Magnesium Deficiency/blood/*chemically induced[MESH] |Magnesium/blood[MESH] |Molecular Targeted Therapy[MESH]Hypomagnesaemia and targeted anti-epidermal growth factor receptor (EG(epmc).pdf DeepDyve Pubget Overpricing